As mentioned above, the broad-spectrum antiparasitic drug IVM, which is widely used in the field of parasitic control, has many advantages that suggest that it is worth developing as a potential new anticancer drug
This triple-action mechanism sets it apart from earlier weight loss peptides like semaglutide (GLP-1 only) or tirzepatide (GLP-1 and GIP), making it one of the most potent metabolic compounds studied to date
doi: 10.1172/jci.insight.140532 [DOI] [PMC free article] [PubMed] [Google Scholar] 7.Silverii GA, Monami M, Gallo M, et al
Ive lost 85 lbs on my tirzepatide journey, and it has truly changed my life
By selecting participants who meet specific health and weight criteria, researchers can better determine who is a candidate for GLP-1 therapies and how these treatments might be used more broadly in the future
Heres the numbers Heres why we chose 10% as a benchmark